The rate of cardiovascular events at 1 year was reduced from 2.18 % in the standard-therapy group to 0.95 % in the evolocumab group ( hazard ratio in the evolocumab group , 0.47 ; 95 % confidence interval , 0.28 to 0.78 ; P = 0.003 ) .